Introduction
Obesity may be de®ned as a syndrome mainly characterized by the presence of an enlarged fat mass due to an imbalance between energy intake and energy expenditure. Hyperinsulinemia and a reduced peripheral insulin sensitivity contribute to this syndrome.
The goal of treatment in such a patient should aim to improve energy expenditure, thus accelerating weight loss, and to improve peripheral glucose metabolism while decreasing insulin resistance and hyperinsulinemia.
Sibutramine (SIB) is a novel antiobesity drug which reduces the bodyweight of animals via a dual mechanism. It reduces food intake by enhancing satiety and it increases energy expenditure by stimulating thermogenesis in brown adipose tissue; both mechanisms result from central inhibition of noradrenaline and 5-hydroxytryptamine reuptake. 1, 2 It has been observed that sibutramine may lead to a decrease in food intake and to a progressive weight loss in animals as well as in man. 3 Furthermore sibutramine was able to induce a signi®cant weight loss in overweight non-insulin-dependent diabetics also inducing a clear improvement in glycemic control. 4 To date it is impossible to conclude for an effect of sibutramine per se on glucose metabolism, since there is no evidence that this effect may be at least partially independent of weight loss. The aim of our study was therefore to assess whether a short term (1 week) treatment with sibutramine may affect insulin sensitivity and glucose metabolism in genetically obese ( faafa) Zucker rats. In particular we investigated the effect of the drug on glucose uptake and turnover, both in basal conditions and during an euglycemic hyperinsulinemic clamp.
Material and methods
Genetically obese ( faafa) male Zucker rats were daily monitored for body weight and food consumption. After pentobarbital anaesthesia two indwelling catheters were positioned in the jugular vein and carotid artery, for infusion and blood sampling respectively, as previously described in detail. 5 Two groups of 7 animals each were used for the evaluation of basal glucose utilization in muscle and adipose tissues. They were administered respectively sibutramine (Knoll), at the dose of 10 mgakg daily p.o., or vehicle as control, for one week preceding the study.
Insulin-dependent glucose uptake in muscle and adipose tissues was studied in three other groups of 7 animals each, which were randomly assigned to control, control pair-fed or SIB-treated group. In the SIB-treated group SIB was administered for the week preceding the clamp at the dose of 10 mg daily p.o. together with water. The control pair-fed rats were prepared to avoid any in¯uence of weight loss on insulin sensitivity; their food intake was matched to an equal amount as the SIB-treated rats. The control group was only administered the vehicle. After the treatment period the three groups of rats underwent an euglycaemic hyperinsulinemic clamp.
Glucose utilization index was evaluated in basal conditions and at the end of clamp by means of injection of a bolus (30 mCi) of the non-metabolizable glucose analogue 2-deoxy-[1-3 H]-D-glucose ([ 3 H]-2DG) according to a previously described method. 2, 4 The glucose utilization index was calculated from the amount of 2-deoxy-1-[ 3 H]-glucose-6-phosphate ([ 3 H]2DGP) measured in different muscle groups as well as in adipose tissues as previously described. 6 Overall glucose turnover was evaluated by euglycemic ± hyperinsulinemic clamp combined with tracer infusion, as previously described. 5 Rats were divided into three groups of 7 animals each and randomly assigned to control, control pair-fed or SIB-treated group, as described above.
Starting 30 min before the insulin infusion rats received a primed (2.25 mCi) infusion (0.15 mCiamin) of H]-D-glucose which was maintained unchanged until the end of the study.
Overall glucose utilization was calculated as the average rate of glucose infusion during the last 20 min of the clamp study plus any residual endogenous glucose production. The rate of the endogenous glucose production was measured by radioisotopic dilution technique. 5 Blood samples for plasma glucose, FFA, lactate and insulin assay were collected from the tail vein before and after 1 week of treatment with SIB or vehicle. We also collected samples from the carotid artery at the end of clamp.
Values are expressed as mean AE s.e.m. Statistical analysis was performed by ANOVA.
Results
Sibutramine treatment p.o. for 7 days decreased both daily food intake (27.8AE 11.73 gad vs 21.3 AE 21.65; P`0.01) and body weight (352AE 17.2 vs 335 AE 22.6 g; P`0.01) in comparison with vehicle-treated rats (370 AE 19 vs 385 AE 16 g; P`0.01).
SIB administration induced no changes in glucose, lactate, FFA and insulin plasma levels.
In SIB-treated animals basal glucose utilization was signi®cantly increased in some muscles and brown adipose tissue versus controls, while no differences were observed in white adipose tissues, diaphragm and heart (Figure 1) .
During euglycemic hyperinsulinemic clamp overall glucose disposal was signi®cantly increased in SIBtreated rats (Figure 2 ) in comparison to both pair-fed and control animals. In contrast no differences in insulin-dependent glucose uptake were found among all tested tissues (data not shown).
The study of the overall glucose turnover by means of the [3-3 H]-D-glucose infusion technique showed that the enhanced glucose infusion rate, observed in SIB-treated rats, was mainly due to a reduction in hepatic glucose production, while R d (rate of glucose disappearance) during clamp resulted in a small but not signi®cant increase in the SIB-treated rats (Figure 2) .
It is noteworthy that our study was performed in an experimental model of obesity, such as faafa Zucker rats, that also exhibit a state of insulin resistance. In these experimental conditions short term sibutramine administration con®rmed the previously observed reduction in both food intake and body weight, also showing an increased basal glucose utilization in some skeletal muscles. This phenomenon was not observed during clamp, suggesting that the improvement of basal peripheral glucose metabolism by sibutramine may recognize a different mechanism from a simple amelioration of the tissue insulin sensitivity. Our experiments do not offer any further explanation for these ®ndings.
On the other hand, we found a decreased glucose infusion rate in SIB-treated animals in comparison to both control and pair-fed rats, mainly due to a reduced Figure 2 Effect of sibutramine treatment in comparison to pairfed and vehicle treated rats on overall glucose turnover during euglycemic hyperinsulinemic clamp. GIR: glucose infusion rate; R d : rate of glucose disappearance; HGP: hepatic glucose production.
* P`0.05 or less by ANOVA. Figure 1 Effect of sibutramine treatment on basal glucose utilization index (GUI) among different tissues (WQ: white quadriceps; RQ: red quadriceps; SOL: soleus; TIB: tibialis; RG: red gastrocnemius; EDL: estensor digitorum longus; SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue; BAT: brown adipose tissue).
* P`0.05 or less by ANOVA.
Sibutramine effect on glucose metabolism R Fabris et al hepatic glucose production. Sustained hyperinsulinemia during clamp was able to signi®cantly reduce the increased hepatic glucose production characteristically present in this strain of rats, 5 thus suggesting an improved insulin sensitivity of the liver induced by sibutramine per se, independently from weight loss. This fact could explain, at least in part, the observed improvement of glycaemic control in non-insulin dependent diabetic subjects, 4 in which the hepatic glucose production represents a major feature of the disease.
